<DOC>
	<DOCNO>NCT01001169</DOCNO>
	<brief_summary>The objective study evaluate immunogenicity safety GSK Biologicals ' investigational influenza vaccine GSK2340274A follow one dose follow second dose , use dosage use H5N1 development program Japanese child age 10-17 year alternative dose child age 6 month 9 year .</brief_summary>
	<brief_title>Safety Immunogenocity Study GSK Biologicals ' Pandemic Influenza ( H1N1 ) Candidate Vaccine Japanese Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Japanese child , male female , age 6 month 17 year time first study vaccination . Written inform consent obtain subject 's parent ( ) LAR ( ) subject . Whenever possible , assent also obtain subject . Healthy child establish medical history clinical examination enter study ( Particular attention must exercise deal patient bronchial asthma ) . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine plan use study period . Clinically virologically confirm influenza infection May 2009 day enrolment . Previous administration novel [ H1N1 ] v vaccine . Administration vaccine within 30 day vaccination plan administration within first vaccination blood sample Day 42 within 30 day prior blood sample Day 182 , exception seasonal influenza vaccine . Administration seasonal influenza vaccine within 14 day vaccination Day 0 , plan administration within first vaccination blood sample Day 42 within 14 day prior blood sample Day 182 . Excessive underweight excessive obesity . ( Under upper 2fold standard deviation weight distribution correspond age group use reference ) . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Acute disease and/or fever time enrolment : Fever define temperature &gt; = 37.5°C oral , axillary tympanic setting , &gt; = 38.0°C rectal setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . History neurological disorder include acute disseminate encephalomyelitis GuillainBarré syndrome , convulsive seizure epilepsy . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin eligible dos give 24 hour study vaccination . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible Any condition , opinion investigator , prevents subject participate study . Child Care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
	<keyword>influenza infection</keyword>
</DOC>